Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the recent resurrection of an investigational human monoclonal antibody targeting beta-amyloid for the treatment of early Alzheimer’s disease (AD).
Question
What is your opinion of the resurrection of aducanumab for AD? (0:05)
Also see linked videos with Bengt Winblad:
Overview of the MOPEAD Project
Emerging therapeutic targets for Alzheimer’s disease
Swedish Geriatric Neurologist Perspective on COVID-19
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
